Predictors of a poor immune response to highly active antiretroviral therapy in patients with a sustained virologic response: The Australian HIV Observational.

Slides:



Advertisements
Similar presentations
Membership and Club Development Bob Lunnon National Vice President.
Advertisements

An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia
Australia BY ALEX MARCHESE. The capital city of Australia is ACT.
High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.
Increased routine screening for syphilis and falling syphilis incidence in HIV positive and HIV negative men who have sex with men: implications for syphilis.
High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa – Implications for HIV and TB Treatment Programs Kogieleum Naidoo on behalf.
Recommendations of BU/HIV expert panel influenced by results from Akonolinga All BU patients should be offered quality provider-initiated HIV testing and.
By Indy and Charlotte. History Every day in many ways the Royal Flying Doctor Service takes the most care to Australia's country people so that anyone.
CINDY SHANNON PRO VICE CHANCELLOR (INDIGENOUS EDUCATION) Barriers to Women Work and Education.
PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.
High Risk Sexual Behaviour in Men Who Have Sex With Men: The Development of a Sexual Risk Behaviour Screening Tool Gibbie T 1,5, Hellard M 2, Ellen S 3,5,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
THE BODY PRO The HIV Resource for Health Care Professionals Copyright © 2009 The HealthCentral Network, Inc. All rights reserved. This activity is jointly.
Antibody and B cell responses may control circulating lipopolysaccharide in patients with HIV infection Lim A 1, Amini A 1, D’Orsogna L 2, Rajasuriar R.
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
Sustained Treatment as Prevention: Unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN K.H.
NEHTA’s vision for personal health records Australian Private Hospitals Association 18 October 2011 Peter Fleming, Chief Executive.
Progress of the Singapore TB Elimination Programme (STEP)
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.
Press Briefing: Office of the Vice Chancellor MUK 6 th September 2010 The Infectious Diseases Institute Care and Research Initiatives Dr Alex G Coutinho.
Improving Services to Aboriginal and Torres Strait Islander Peoples: The ABCD Extension Project.
Clinical and mycological determinants of Cryptococcosis-associated IRIS (C-IRIS) Chang CC, Elliott JE, Gosnell BI, Dorasamy AA, Omarjee S, Naranbhai V,
Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Regulatory T cell abnormalities associated with aberrant CD4+ T-cell responses in HIV+ patients with immune reconstitution disease (IRD) Nabila SEDDIKI.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
Australia By Elizabeth & Sammy-Jo
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Aspects of HIV in Denmark Jane Agergaard, MD, PhD Department of Infectious Diseases Aarhus University Hospital Skejby Denmark.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influence of the Timing of Antiretroviral Therapy.
Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Hepatitis B and C virus Coinfection in the TREAT Asia HIV Observational Database Zhou J 1, Zhang FJ 2, Lim PL 3, Dore GJ 1, Chen YMA 4 on behalf of The.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Anal and Cervical Cytologic Abnormalities among HIV-Infected Women on HAART Remain Prevalent at 12 months in the Study to Understand the Natural History.
Treatment and Care, and Clinical Research Basil Donovan National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; and Sydney.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:
A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:
Tips for Protecting Your Intellectual Property
Trademarking your Company
Theme: Australia today
Earlier treatment and lower mortality in infants Initiating ART at
Faculty of Population Health Dean: Graham Hart
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Utilizing research as an opportunity to strengthen
John de Wit1,2, Dean Murphy2,3, Luxi Lal4,5,6, Jennifer Audsley5,7, Christopher K. Fairley8,9, Mark Stoove4,10, Norm Roth11, Richard Moore12, Ban K.
AAHBC Convened in 1997 Originally titled the National Allied Health Benchmarking Consortium (NAHBC) Founded to facilitate the development of a standardised.
What is a Health Care Home?
Hepatitis C in the HIV-infected patient
Presentation transcript:

Predictors of a poor immune response to highly active antiretroviral therapy in patients with a sustained virologic response: The Australian HIV Observational Database Kathleen Glenday 1, Kathy Petoumenos 1, John Chuah 2, Anne Mijch 3, Brian Mulhall 4, Mark Kelly 5 and David A Cooper 1,6 on behalf of the Australian HIV Observational Database 1 National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia 2 Gold Coast Sexual Health Clinic, Gold Coast, Australia 3 The Alfred Hospital, Melbourne, Australia 4 University of Sydney, Sydney, Australia 5 AIDS Medical Unit, Brisbane, Australia 6 St Vincent’s Hospital, Sydney, Australia

Predictors of a poor immune response (<200 cells/µL) to HAART in patients with sustained virological suppression *significant in univariate analysis only. OR adjusted for mode of HIV-infection, prior AIDS, prior HCV infection, baseline HIV RNA and CD4. †CD4+ T-cell nadir prior to commencing the inclusion regimen Other covariates tested for inclusion in the model that were non-significant include prior ART, NNRTI- vs. PI-based regimens, AZT vs. d4T containing regimens, year started regimen, year of HIV infection, first/second HAART regimen, age, sex, increasing vs. decreasing CD4 count prior to start of HAART, HBV.

Key Findings Predictors of a poor immune response (<200 cells/µL): Immune status prior to commencing ART HCV co-infection Mode of infection other than MSM (with or without IDU) Prior ART & type of ART regimen NOT significantly associated with poor immune response outcome No significant difference by immune response group in time to AIDS or death in this analysis

The Australian HIV Observational Database Acknowledgements D Ellis, General Medical Practice, Coffs Harbour, NSW; J Chuah*, D Lester, W Fankhauser, B Dickson, Gold Coast Sexual Health Clinic, Miami, QLD; M Bloch, T Franic, S Agrawal, Holdsworth House General Practice, Darlinghurst, NSW; J Anderson, P Cortissos, The Carlton Clinic, Carlton, VIC; S Mallal, C Forsdyke, S Bulgannawar, Department of Clinical Immunology, Royal Perth Hospital, Perth, WA; NJ Roth*, J Nicholson, Prahran Market Clinic, South Yarra, VIC; D Allen, Holden Street Clinic, Gosford, NSW; D Smith, C Mincham, Lismore Sexual Health & AIDS Services, Lismore, NSW; D Baker*, R Vale, 407 Doctors, Surry Hills, NSW; D Russell, J Leamy, C Remington, Cairns Sexual Health Service, Cairns, QLD; C O’Connor; Royal Prince Alfred Hospital Sexual Health, Camperdown, NSW; D Sowden, A Walker*, Clinic 87, Sunshine Coast & Cooloola HIV Sexual Health Service, Nambour, QLD; D Orth; D Youds, Gladstone Road Medical Centre, Highgate Hill, QLD; E Jackson, D Hunter, K McCallum, Blue Mountains Sexual Health and HIV Clinic, Katoomba, NSW; T Read, J Silvers, Melbourne Sexual Health Centre, Melbourne, VIC; A Kulatunga, P Knibbs, Communicable Disease Centre, Royal Darwin Hospital, Darwin, NT; A Mijch, J Hoy, K Watson*, M Bryant, The Alfred Hospital, Melbourne, VIC; M Gotowski, S Taylor, L Stuart-Hill, Bligh Street Clinic, Tamworth, NSW; D Cooper, A Carr, M Lacey, K Hesse, St Vincent’s Hospital, Darlinghurst, NSW; R Finlayson, I Prone, Taylor Square Private Clinic, Darlinghurst, NSW; MT Liang, Nepean Sexual Health and HIV Clinic, Penrith, NSW; M Kelly, P Negus, H Magon, AIDS Medical Unit, Brisbane, QLD; K Brown, N Skobalj, Illawarra Sexual Health Clinic, Warrawong, NSW; L Wray, H Lu, Sydney Sexual Health Centre, Sydney, NSW; W Donohue, A Lohmeyer, The Care and Prevention Programme, Adelaide University, Adelaide, SA; I Woolley, Monash Medical Centre, Clayton, VIC; Dubbo Sexual Health Centre, Dubbo, NSW; P Canavan*, National Association of People living with HIV/AIDS; C Lawrence*, National Aboriginal Community Controlled Health Organisation; I Zablotska*, National Centre in HIV Social Research, University of NSW, Sydney; B Mulhall*, Department of Public Health and Community Medicine, University of Sydney, Sydney, NSW; M Law*, K Petoumenos*, K Glenday*, National Centre in HIV Epidemiology and Clinical Research, University of NSW, Sydney; NSW. *Steering Committee member , † Current Steering Committee chair The Australian HIV Observational Database is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) (Grant No. U01-AI069907). The National Centre in HIV Epidemiology and Clinical Research is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales.